| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28905 |
| 来源ID | Working Paper 28905 |
| Funding Risky Research | |
| Chiara Franzoni; Paula Stephan; Reinhilde Veugelers | |
| 发表日期 | 2021-06-14 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | The speed with which Covid-19 vaccines were developed and their high-performance underlines how much society depends on the pace of scientific research and how effective science can be. This is especially the case for vaccines based on the new designer mRNA technology. We draw on this exceptional moment for science to reflect on whether the government funding system is sufficiently supportive of research needed for key breakthroughs, and whether the system of funding encourages sufficient risk-taking to induce scientists to explore transformative research paths. We begin with a discussion of the challenges faced by scientists who did pioneering-research related to mRNA-based drugs in getting support for research. We describe measures developed to distinguish risky from non-risky research and their citation footprint. We review empirical work suggesting that funding is biased against risky research and provide a framework for thinking about why principal investigators, panelists and funding agencies may eschew risky research. We close with a discussion of interventions that government agencies and universities could follow if they wish to avoid a bias against risk. |
| 主题 | Health, Education, and Welfare ; Education ; Development and Growth ; Innovation and R& ; D ; COVID-19 |
| URL | https://www.nber.org/papers/w28905 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586579 |
| 推荐引用方式 GB/T 7714 | Chiara Franzoni,Paula Stephan,Reinhilde Veugelers. Funding Risky Research. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28905.pdf（258KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
